These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21698649)

  • 21. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
    Mortensen SA; Rosenfeldt F; Kumar A; Dolliner P; Filipiak KJ; Pella D; Alehagen U; Steurer G; Littarru GP;
    JACC Heart Fail; 2014 Dec; 2(6):641-9. PubMed ID: 25282031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy.
    Fang Y; McDonald CM; Clemens PR; Gordish HD; Illei K; Hoffman EP; ; Dang UJ
    J Neuromuscul Dis; 2023; 10(3):349-364. PubMed ID: 36806514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Permanent muscular sodium overload and persistent muscle edema in Duchenne muscular dystrophy: a possible contributor of progressive muscle degeneration.
    Weber MA; Nagel AM; Wolf MB; Jurkat-Rott K; Kauczor HU; Semmler W; Lehmann-Horn F
    J Neurol; 2012 Nov; 259(11):2385-92. PubMed ID: 22544297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy.
    Tsabari R; Simchovitz E; Lavi E; Eliav O; Avrahami R; Ben-Sasson S; Dor T
    Neuromuscul Disord; 2021 Sep; 31(9):803-813. PubMed ID: 34304968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy.
    Latkovskis G; Saripo V; Sokolova E; Upite D; Vanaga I; Kletnieks U; Erglis A
    Medicina (Kaunas); 2016; 52(3):171-9. PubMed ID: 27496187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
    Wein N; Alfano L; Flanigan KM
    Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials.
    Schreiber A; Brochard S; Rippert P; Fontaine-Carbonnel S; Payan C; Poirot I; Hamroun D; Vuillerot C;
    Dev Med Child Neurol; 2018 Feb; 60(2):185-191. PubMed ID: 28990163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.
    Nagy S; Hafner P; Schmidt S; Rubino-Nacht D; Schädelin S; Bieri O; Fischer D
    Trials; 2019 Nov; 20(1):637. PubMed ID: 31752977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early prednisone treatment in Duchenne muscular dystrophy.
    Merlini L; Cicognani A; Malaspina E; Gennari M; Gnudi S; Talim B; Franzoni E
    Muscle Nerve; 2003 Feb; 27(2):222-7. PubMed ID: 12548530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
    Lennie JL; Mondick JT; Gastonguay MR
    J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
    Alman BA; Raza SN; Biggar WD
    J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: A randomized, open-label trial.
    Kochar GS; Sondhi V; Kabra SK; Yadav SL; Dwivedi SN; Gulati S
    Muscle Nerve; 2022 Jan; 65(1):60-66. PubMed ID: 34617309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The natural history of the patients with Duchenne muscular dystrophy in Taiwan: A medical center experience.
    Liang WC; Wang CH; Chou PC; Chen WZ; Jong YJ
    Pediatr Neonatol; 2018 Apr; 59(2):176-183. PubMed ID: 28903883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vitamin D in corticosteroid-naïve and corticosteroid-treated Duchenne muscular dystrophy: what dose achieves optimal 25(OH) vitamin D levels?
    Alshaikh N; Brunklaus A; Davis T; Robb SA; Quinlivan R; Munot P; Sarkozy A; Muntoni F; Manzur AY;
    Arch Dis Child; 2016 Oct; 101(10):957-61. PubMed ID: 27246070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC
    Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine.
    Slater SK; Nelson TD; Kabbouche MA; LeCates SL; Horn P; Segers A; Manning P; Powers SW; Hershey AD
    Cephalalgia; 2011 Jun; 31(8):897-905. PubMed ID: 21586650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
    Hendriksen RGF; Lionarons JM; Hendriksen JGM; Vles JSH; McAdam LC; Biggar WD
    J Neuromuscul Dis; 2017; 4(3):217-236. PubMed ID: 28800336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
    Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
    J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antioxidants for Treatment of Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
    Ren S; Yao C; Liu Y; Feng G; Dong X; Gao B; Qian S
    Eur Neurol; 2022; 85(5):377-388. PubMed ID: 35697003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.